NCT00673868View on ClinicalTrials.gov

Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 6, 2008

Study Completion Date

August 6, 2008

Conditions
Cytomegalovirus Infections
Interventions
BIOLOGICAL

CMV Specific Cytotoxic T Lymphocytes

CMV Specific Cytotoxic T Lymphocytes will be infused between days 30 and 40 post-transplant at a dose ranging from 2- 5 x e5 cells/kg.

Trial Locations (1)

17033

Penn State University, Hershey

All Listed Sponsors
lead

Milton S. Hershey Medical Center

OTHER

NCT00673868 - Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants | Biotech Hunter | Biotech Hunter